News coverage about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has trended somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.5341970301405 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
Shares of NASDAQ IPCI remained flat at $$0.47 during trading hours on Monday. The company had a trading volume of 256,491 shares, compared to its average volume of 337,759. The firm has a market capitalization of $20.45 million, a price-to-earnings ratio of -1.62 and a beta of 1.42. IntelliPharmaCeutics Intl has a twelve month low of $0.32 and a twelve month high of $2.92.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last issued its earnings results on Monday, April 16th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The firm had revenue of $0.34 million during the quarter, compared to analyst estimates of $1.23 million. IntelliPharmaCeutics Intl had a negative net margin of 217.52% and a negative return on equity of 2,811.75%. sell-side analysts forecast that IntelliPharmaCeutics Intl will post -0.1 EPS for the current fiscal year.
A number of research analysts have recently commented on the company. Zacks Investment Research lowered IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Saturday, June 2nd. Maxim Group reiterated a “hold” rating and set a $8.00 price target on shares of IntelliPharmaCeutics Intl in a report on Friday. ValuEngine upgraded IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Finally, HC Wainwright set a $3.00 target price on IntelliPharmaCeutics Intl and gave the company a “buy” rating in a research note on Tuesday, May 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.65.
IntelliPharmaCeutics Intl Company Profile
IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.